



Can-Fite BioPharma was Granted a US Patent for its 3rd drug candidate CF602 earmarked for the Treatment of Sexual Dysfunction

Based on reports from clinical trials conducted with other company drugs, Can-Fite will develop the CF602 drug for the treatment of sexual dysfunction

Petach Tikva, Israel, July 3, 2013: Can-Fite BioPharma (TASE: CFBI, OTC: CANFY), a biotechnology company with a pipeline of proprietary small molecule drugs that address inflammatory and cancer diseases, announced today that the USPTO granted a US patent to its 3rd drug candidate CF602. The patent grant strengthens the intellectual property of the Company and enables developing CF602 for the treatment of sexual dysfunction, a \$3 Billion potential market.

The granted patent includes a family of allosteric modulators enhancing the affinity of the natural ligand adenosine to its A3 adenosine receptor. These compounds were developed in cooperation with 2 worldwide Medicinal Chemists, Professor Ijzerman from Leiden University, Netherlands, and Professor Jacobson, NIH, US, accordingly. The patent was licensed to Can-Fite from the Leiden University, which was cooperating with to the NIH.

During clinical studies conducted with other drugs of the company, patients suffering from sexual dysfunction reported that they returned to normal function following the treatment with the company drugs. The Company believes that these findings are correlated with the Company's platform technology, which is the targeting of the A3 Adenosine Receptor (A3AR). Adenosine, like nitric oxide, is a potent and short-lived vaso-relaxant that functions via intracellular signaling (in particular, through cAMP) to promote smooth muscle relaxation. CF602 has demonstrated proof of concept for anti-inflammatory activity in *in vitro* and *in vivo* studies performed by the Company in low dosages and without any side effects.

Can-Fite CEO Pnina Fishman, Ph.D., commented, "We are very pleased with the grant of the US patent which will enable us to expand our pipeline and develop our next generation drug candidates. We believe, following examining the clinical data gathered, that CF602 can be utilized for the treatment of sexual dysfunction. The grant of the US patent demonstrates the innovation of our platform technology".

About CF602

CF602 is an orally bioavailable small molecule, which enhances the affinity of the natural ligand, adenosine, to its A3AR. The advantage of this molecule is its capability to target specific areas where adenosine levels are increased. Normal body cells and tissues are refractory to allosteric modulators. This approach complements the basic platform technology of Can-Fite, utilizing the Gi coupled protein A3AR as a potent target in inflammatory diseases. CF602 has demonstrated proof of concept for anti-inflammatory activity in *in vitro* and *in vivo* studies performed by the Company.

About Can-Fite Biopharma Ltd.

Can-Fite Biopharma Ltd is an Israeli public company, the ordinary shares of which are traded on the Tel Aviv Stock Exchange (TASE: CFBI). American Depository Receipts of the company are traded on the over-the-counter market (OTC: CANFY). The company, which commenced business activity in 2000, was founded by Pnina Fishman, Ph.D., researcher in the Rabin Medical Center, and Ilan Cohn Ph.D., patent attorney and senior partner at Reinhold Cohn Patent Attorneys. Pnina Fishman serves as CEO of the company. The company was founded on the basis of Fishman's scientific findings, and is focused on the development of small molecule orally bioavailable drugs, ligands to the A3 adenosine receptor. The latter mediates anti-inflammatory and anti-cancer effects and is suggested as a biological predictive marker. The company's lead drug, CF101, is in clinical development for the treatment of autoimmune inflammatory diseases. The CF102 drug candidate is being developed for the treatment of liver diseases. Can-Fite has a wealth of clinical experience: to date, more than 700 patients have participated in clinical trials conducted by the company. Can-Fite previously licensed its activity in the ophthalmic field to Ophthalix Inc., in which it holds a controlling interest (OTC: OPLI).

Contact:

KCSA Strategic Communications
Jeff Corbin / Phil Carlson
jcorbin@kcsa.com / pcarlson@kcsa.com
212-896-1233

Safe Harbor Statement

Any statements in this press release that relate to the Company's expectations are forward-looking statements, within the meaning of the Private Securities Litigation Reform Act. The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees. Since this information may involve risks and uncertainties and are subject to change at any time, the Company's actual results may differ materially from expected results. Additional risks associated with Can-Fite's business can be found in its periodic filings with the Tel Aviv Stock Exchange.